Comparison of efficacy between adjuvant chemotherapy and chemoradiation therapy for pancreatic cancer: AJCC stage-based approach

Table 1 Baseline characteristics

Variables	n = 335
Age	63.5 ± 9.1
Female/male	143 (42.7)/192 (57.3)
ECOG
0	275 (82.1)
1	60 (17.9)
Charlson's comorbidity index	4.6 ± 1.3
Tumor location, n (%)
Head/uncinate	215 (64.2)
Body	54 (16.1)
Tail	54 (16.1)
Overlapping	12 (3.6)
Surgery type, n (%)
Pancreaticoduodenectomy	222 (66.3)
Distal pancreatectomy	102 (30.4)
Total pancreatectomy	7 (2.1)
Subtotal pancreatectomy	4 (1.2)
Differentiation, n (%)
WD	24 (7.2)
MD	268 (80.0)
PD	29 (8.7)
UD	3 (0.9)
Unknown	11 (3.3)
AJCC stage, n (%)
IA	46 (13.7)
IB	90 (26.9)
IIA	12 (3.6)
IIB	128 (38.2)
III	59 (17.6)
Lymphovascular invasion, n (%)	196 (58.9)
Perineural invasion, n (%)	280 (83.6)
Preoperative laboratory findings
WBC as × 103 cells/µL	6.1 ± 1.8
Hb in g/dL	12.9 ± 1.5
AST in IU/L	43.4 ± 49.6
ALT in IU/L	66.4 ± 93.7
ALP in IU/L	159.3 ± 165.1
Albumin in mg/dL	4.2 ± 3.5
Total bilirubin in mg/dL	2.2 ± 3.6
Creatinine in mg/dL	0.8 ± 0.2
CA 19-9 in U/mL	623.2 ± 1491.9
CEA in ng/mL	22.4 ± 307.2
Duration to initial adjuvant treatment in d	47.5 ± 17.7
Follow-up duration in mo	32.2 ± 28.6

AJCC: American Joint Committee on Cancer; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CA 19-9: Carbohydrate antigen 19-9; CEA: Carcinoembryonic antigen; ECOG: Eastern Cooperative Oncology Group; Hb: Hemoglobin; MD: Moderately differentiated; PD: Poorly differentiated; UD: Undifferentiated; WBC: White blood cell; WD: Well differentiated.